| Literature DB >> 25929241 |
Yanting Sun1, Boli Hu2, Chengfei Fan1, Lu Jia1, Yina Zhang1, Aifang Du1, Xiaojuan Zheng1,3, Jiyong Zhou1,2,3.
Abstract
Infectious bursal disease virus (IBDV) enters the host cells via endocytic pathway to achieve viral replication in the cytoplasm. Here, we performed LC-MS/MS coupled with isobaric tags for relative and absolute quantification labeling of differentially abundant proteins of IBDV-infected cells using a subcellular fractionation strategy. We show that the viral infection regulates the abundance and/or subcellular localization of 3211 proteins during early infection. In total, 23 cellular proteins in the cytoplasmic proteome and 34 in the nuclear proteome were significantly altered after virus infection. These differentially abundant proteins are involved in such biological processes as immune response, signal transduction, RNA processing, macromolecular biosynthesis, energy metabolism, virus binding, and cellular apoptosis. Moreover, transcriptional profiles of the 25 genes corresponding to the identified proteins were analyzed by quantitative real-time RT-PCR. Ingenuity Pathway Analysis clustered the differentially abundant proteins primarily into the mTOR pathway, PI3K/Akt pathway, and interferon-β signaling cascades. Confocal microscopy showed colocalization of the viral protein VP3 with host proteins heterogeneous nuclear ribonucleoprotein H1, nuclear factor 45, apoptosis inhibitor 5, nuclear protein localization protein 4 and DEAD-box RNA helicase 42 during the virus infection. Together, these identified subcellular constituents provide important information for understanding host-IBDV interactions and underlying mechanisms of IBDV infection and pathogenesis.Entities:
Keywords: IBDV-infected cells; Subcellular proteomics; iTRAQ
Mesh:
Substances:
Year: 2015 PMID: 25929241 PMCID: PMC7163642 DOI: 10.1002/elps.201500014
Source DB: PubMed Journal: Electrophoresis ISSN: 0173-0835 Impact factor: 3.535
Figure 1Confirmation of DF‐1 cells infected with IBDV. (A) Detection of IBDV in DF‐1 cells with IFA. Mock‐ and IBDV‐infected DF‐1 cells were collected at 12, 18, 21, and 24 hpi and stained with mAb to IBDV VP3 protein followed by FITC‐labeled IgG (green). (B) Quantification of infected cells by flow cytometry. IBDV‐ and mock‐infected DF‐1 cells were assayed by single‐color flow cytometric analysis. This figure shows the percentage of IBDV‐infected cells at 24 hpi. Cells were stained with anti‐VP4 mAb labeled with FITC. Mock‐infected DF‐1 cells served as a negative control (blue line). The mean percentage ± SD of infected cells from a representative experiment performed in triplicate was 99.4 ± 0.2%. (C) Detection of the cytoplasmic and nuclear fractions from IBDV‐ and mock‐infected cells by Western blotting. GAPDH and histone H3 were used as markers of cytoplasmic and nuclear proteins, respectively. IBDV viral proteins VP3 and VP4 were used as markers of infection.
Differentially abundant proteins in IBDV‐infected DF‐1 cells by iTRAQ analysis. The 57 unique proteins identified
| UniProt data | Protein | Gene | Sequence | Unique | p | Ratio |
| Function |
|---|---|---|---|---|---|---|---|---|
| protein ID | name | symbol | coverage | peptides | value | |||
|
| ||||||||
| P18302 | Drebrin | DBN1 | 2.1 | 1 | 4.16 | 2.22 | 0.00006 | Actin binding and profilin binding |
| F1P3J2 | Uncharacterized | IFIT5 | 2.4 | 1 | 5.50 | 2.00 | 0.00018 | Type I interferon mediated signaling pathway |
| F1NJ08 | Vimentin | VIM | 31.3 | 13 | 4.85 | 1.64 | 0.00001 | Integrity of the cytoplasm, immune response |
| E1C2F2 | Pinpin | PNN | 1.9 | 1 | 6.71 | 1.58 | 0.01102 | Participates in the regulation of alternative pre‐mRNA splicing |
| F1NEG6 | Uncharacterized | hnRNPH1 | 4.6 | 3 | 5.50 | 1.51 | 0.00714 | mRNA processing |
| P13648 | Lamin A | Lamin A | 3.3 | 2 | 6.93 | 1.47 | 0.01063 | Structural molecule activity protein binding |
| P16039 | Nucleophosmin | NPM1 | 21.4 | 6 | 4.39 | 1.42 | 0.00008 | Transcription coactivator activity |
| Q9YIC3 | FK506‐binding protein 9 | FKBP | 2.8 | 1 | 4.76 | 1.42 | 0.00302 | Peptidyl‐prolyl |
| F1NZA1 | Uncharacterized | TTLL12 | 3 | 2 | 4.84 | 1.37 | 0.00084 | Cellular protein modification process |
| Q5F3D2 | Uncharacterized | hnRNPH3 | 9.4 | 2 | 7.13 | 1.33 | 0.00204 | Involved in the splicing process and participates in early heat shock‐induced splicing arrest |
| Q07598 | Nonspecific lipid‐transfer protein | SCP2 | 2 | 1 | 8.30 | 1.33 | 0.00102 | Fatty‐acyl‐CoA binding and receptor binding transfer protein |
| E1C8Y9 | Uncharacterized | SRF3 | 17.1 | 3 | 12.14 | 1.29 | 0.03277 | mRNA processing and regulating alternative splicing |
| Q5ZML3 | Serine/arginine‐rich splicing factor 1 | SRSF1 | 30 | 8 | 6.95 | 1.27 | 0.00051 | mRNA processing and regulating alternative splicing |
| E1BQK9 | Uncharacterized | CUL4B | 1.4 | 1 | 8.03 | 1.25 | 0.02890 | Ubiquitin protein ligase binding |
| Q5F3E8 | BTB/POZ domain containing adapter for CUL3‐mediated RhoA degradation protein 3 | TNFAIP1 | 4.8 | 1 | 7.88 | 1.25 | 0.01300 | Negative regulation of Rho protein signal transduction |
| F1NZD3 | Uncharacterized | RBMX | 11.2 | 4 | 10.49 | 1.23 | 0.00049 | Plays several role in the regulation of pre‐ and posttranscriptional processes |
| P09102 | Protein disulfide isomerase | PDIA1 | 12 | 7 | 4.42 | 1.20 | 0.01984 | Protein disulfide oxidoreductase activity |
| I3VQH4 | Interleukin enhancer binding factor 3 | ILF3 | 4.3 | 1 | 9.14 | 1.17 | 0.0005 | Double‐stranded RNA binding and RNA binding |
| H9KZT7 | Uncharacterized | NF45 | 5.9 | 2 | 5.10 | 1.10 | 0.0459 | Double‐stranded RNA binding and RNA binding |
|
| ||||||||
| E1C115 | Uncharacterized | EIF4EBP1 | 7.8 | 1 | 4.39 | 0.83 | 0.00097 | Eukaryotic initiation factor 4E binding |
| Q90ZG0 | Peptidyl‐prolyl | PPIA | 25 | 2 | 8.48 | 0.83 | 0.00057 | Mediates ERK1/2 activation |
| A7UEA7 | Multifunctional protein ADE2 | PAICS | 8.5 | 4 | 8.33 | 0.82 | 0.00022 | Purine nucleobase biosynthetic process |
| E1BYW9 | Proteasome subunit beta type | PSMB3 | 4.4 | 1 | 5.05 | 0.81 | 0.00195 | Cleave peptides in an ATP/ubiquitin‐dependent process in a nonlysosomal pathway |
| F1NNS8 | Uncharacterized | PRDX4 | 5.2 | 1 | 8.57 | 0.77 | 0.01341 | Activation of the transcription factor NF‐kappa B |
| F1NY51 | Uncharacterized | UCHL3 | 10 | 2 | 4.64 | 0.77 | 0.01857 | Catalyze the removal of ubiquitin from polypeptides |
|
| ||||||||
| E1C2Y5 | C‐C Motif chemokine 4 homolog | CCL4 | 8.9 | 4 | 9.33 | 1.96 | 0.00758 | Receptor for a C‐C type chemokine |
| E1C8B5 | Uncharacterized | KIN | 5.6 | 2 | 9.49 | 1.39 | 0.00504 | DNA replication and the cellular response to DNA damage |
| Q5ZK63 | Activated RNA polymerase II transcriptional coactivator p15 | TCP4 | 44.4 | 3 | 10.29 | 1.38 | 0.00188 | Transcription coactivator activity |
| Q5ZL92 | Eukaryotic translation initiation factor 6 | EIF6 | 19.1 | 11 | 4.30 | 1.37 | 0.00621 | Translation initiation factor activity |
| F1NH66 | Uncharacterized | EML4 | 1.6 | 1 | 6.25 | 1.30 | 0.00005 | May modify the assembly dynamics of microtubules |
| Q5ZJK3 | Signal transducer and activator of transcription | STAT1 | 12.2 | 8 | 5.80 | 1.26 | 0.00065 | Mediates cellular responses to interferons |
| F1NZJ2 | Uncharacterized | HK1 | 18.6 | 1 | 6.72 | 1.26 | 0.03647 | Metabolism pathways |
| F1P222 | LDLR chaperone MESD | MESDC2 | 30.2 | 7 | 6.80 | 1.22 | 0.00101 | Acts as a modulator of the Wnt pathway |
| E1C214 | Ubiquitin carboxyl terminal hydrolase 16 isoform x2 | UBP16 | 1.5 | 1 | 5.75 | 1.22 | 0.00004 | Ubiquitin‐specific protease activity |
| F1NA16 | Uncharacterized | SREK1 | 2.1 | 1 | 10.69 | 1.22 | 0.03237 | Participates in the regulation of alternative splicing |
| E1BZH9 | Uncharacterized | HADH | 15.2 | 5 | 9.16 | 1.21 | 0.00227 | Metabolic pathways |
| E1BVT3 | Malate dehydrogenase | MDH2 | 52.5 | 16 | 8.73 | 1.21 | 0.00038 | Operates in the metabolic coordination between cytosol and mitochondria |
| F1NR57 | Uncharacterized | SLC2A11 | 1.9 | 2 | 6.89 | 1.20 | 0.00054 | Facilitative glucose transporter |
| O93257 | X‐ray repair cross‐complementing protein | XRCC6 | 9.2 | 5 | 6.02 | 1.20 | 0.03621 | ssDNA‐dependent ATP‐dependent helicase |
| E1BZJ3 | Uncharacterized | NPL4 | 8.9 | 4 | 6.34 | 1.11 | 0.0075 | Protein binding and zinc ion binding |
| Q5ZMW3 | Apoptosis inhibitor | API5 | 44.4 | 3 | 7.45 | 1.10 | 0.0071 | Inhibiting apoptosis |
|
| ||||||||
| F1NRD9 | ATP‐dependent RNA helicase | DDX1 | 19.5 | 11 | 6.89 | 0.93 | 0.0291 | Enhance NF‐kappa B mediated transcriptional activation |
| E1C2E3 | Uncharacterized | VDAC3 | 20.5 | 6 | 9.25 | 0.85 | 0.0500 | Porin activity and nucleotide binding |
| F1NPD3 | 60S ribosomal protein l18a | RPL18A | 17 | 3 | 11.40 | 0.83 | 0.00034 | Structural constituent of ribosome and RNA |
| Q5ZMD0 | Uncharacterized | NOP56 | 6.2 | 3 | 9.65 | 0.82 | 0.00327 | Involved in the early to middle stages of 60S ribosomal subunit biogenesis |
| F1NC34 | Uncharacterized | SLC35B2 | 4.9 | 2 | 9.33 | 0.82 | 0.01273 | May indirectly participate in activation of the NF‐kappa B and MAPK pathways |
| P53449 | Fructose‐bisphosphate aldolase C | ALDOC | 35.8 | 3 | 6.51 | 0.82 | 0.00034 | Glycolytic enzymes |
| A0M8T8 | Caveolin‐1 | CAV1 | 24.2 | 4 | 6.23 | 0.82 | 0.02114 | Structural molecule activity and receptor binding activity and receptor binding |
| Q5ZJZ5 |
| BDH1 | 3.2 | 1 | 9.58 | 0.82 | 0.01216 | Phospholipid binding and 3‐hydroxybutyrate dehydrogenase activity |
| E1C6C9 | Uncharacterized | NDUFB10 | 12 | 2 | 6.27 | 0.82 | 0.03815 | NADH dehydrogenase (ubiquinone) activity |
| Q7T2Z7 | Collagen alpha‐1 chain | COL1A1 | 3.8 | 1 | 7.47 | 0.81 | 0.00414 | Cell growth and repair |
| Q5ZMF9 | Uncharacterized | DERL1 | 4.4 | 1 | 9.58 | 0.81 | 0.01588 | Participate in the endoplasmic reticulum associated degradation response |
| P22451 | 60S ribosomal protein l5 | RPL5 | 22.9 | 7 | 10.22 | 0.80 | 0.00758 | RNA binding |
| P61355 | 60S ribosomal protein l27 | RPL27 | 18.4 | 3 | 11.23 | 0.80 | 0.01773 | Structural constituent of ribosome |
| F1N9I7 | Probable carboxypeptidase pm20d1 | PM20D1 | 1.5 | 1 | 7.22 | 0.79 | 0.04083 | Metabolic process |
| F1P0H9 | Collagen alpha‐2 (I) chain | COL1A2 | 26.8 | 25 | 9.68 | 0.79 | 0.01093 | Cell growth and repair |
| F1NH93 | Uncharacterized | RPS20 | 19.7 | 2 | 10.71 | 0.77 | 0.00008 | Structural constituent of ribosome and RNA binding |
| Q5F491 | Uncharacterized | DDX42 | 22 | 11 | 6.99 | 0.77 | 0.0004 | RNA binding and ATP‐dependent helicase activity |
| Q2MCJ7 | Aquaporin‐1 | AQP1 | 7.4 | 1 | 6.91 | 0.76 | 0.00052 | Water channel activity and transporter activity |
| F1NFE0 | Collagen alpha‐1(VI) chain | COL6A1 | 18.1 | 14 | 5.65 | 0.76 | 0.01548 | Acts as a cell‐binding protein |
| F1NJT3 | Fibronectin | FINC | 16.1 | 34 | 5.34 | 0.74 | 0.00113 | Involved in cell adhesion and migration processes |
| P15988 | Collagen alpha‐2 (VI) chain | COL6A2 | 16.9 | 16 | 5.61 | 0.74 | 0.00006 | Acts as a cell‐binding protein |
| P02457 | Collagen alpha‐1 (I) chain | COL1A1 | 45.6 | 45 | 5.21 | 0.73 | 0.00004 | Cell growth and repair |
a) Protein IDs according to UniProt.
b) Protein name of the proteins identified by iTRAQ with LC‐MS/MS.
c) Percent sequence coverage of identified proteins.
d) Number of unique peptides identified for each protein (in three independent biological replicates).
e) Ratios of IBDV‐infected/mock‐infected.
f) p‐Value of significant index.
Figure 2Statistical analysis of quantitative subcellular proteomic data from IBDV‐infected DF‐1 cells. (A) Quantitative analysis using numbers of differentially abundant proteins in cytoplasmic and nuclear fractions. (B) Hierarchical cluster analysis for differentially abundant proteins in cytoplasmic and nuclear fractions. Differentially abundant proteins are shown with a pseudocolor scale (from −3 to 3) indicating high (red) and low (green) abundance. (C) Classification of proteins in different fractions using gene ontology. All identified proteins in cytoplasmic, nuclear, lysosomal, mitochondrial, and endoplasmic reticulum were annotated.
Figure 3Biological processes analysis of differentially abundant proteins based on gene ontology. (A) Relative proportions of various proteins that were increased or decreased in abundance in the cytoplasmic fraction. (B) Relative proportions of various proteins that were increased or decreased in abundance in the nuclear fraction. Percentages of protein numbers in each category are displayed in brackets.
Figure 4Transcriptional profiling of differentially abundant proteins in IBDV‐infected DF‐1 cells. The mRNA changes of IBDV‐infected cells was detected by real‐time RT‐PCR. All samples were normalized to the GAPDH gene as a control. The fold increase or decrease was relative to mock‐infected cells as the reference. Error bars represent SDs.
Figure 5Western blot analysis of selected differentially abundant proteins in cytoplasmic and nuclear fractions of IBDV‐infected cells. The differentially abundant proteins NF45 was increased in the cytoplasmic fraction and translocated from nucleus to the cytoplasm upon virus infection. Equal amounts of protein fractions were loaded, and the abundance of IFIT5, hnRNPH1, NF45, API5, STAT1, and viral protein VP3 were determined using specific pAbs/mAbs. Mock‐infected cells were used as a negative control. GAPDH and histone 3 were used as the marker and loading control for the cytoplasm and nucleus, respectively.
Figure 6Immunofluorescence analysis of subcellular distribution of cellular NF45, hnRNPH1, DDX42, NPL4, and API5 with IBDV VP3 protein by confocal microscopy. IBDV‐infected DF‐1 cells reacted with anti‐VP3 mAb and anti‐hnRNPH1, anti‐NF45, anti‐API5, anti‐NPL4, or anti‐DDX42 pAbs as a primary antibody, followed by the FITC‐conjugated (green) goat/rabbit IgG and Alexa Fluor 546 conjugated (red) mouse IgG. The fixed cell nuclei were stained with DAPI (blue).
Figure 7Signaling pathways in subcellular fractions significantly affected by virus infection. (A) Top 11 signaling pathways in the cytoplasmic proteome. (B) Top 10 signaling pathways in the nuclear proteome. Cononical pathway analysis were conducted by IPA software. The pathway involved was shown by p‐value of regulated proteins. The ratio represented that number reached threshold criteria divided total number of the given pathway.
Figure 8Analysis of interaction network pathway for identified proteins in cytoplasmic fraction (A) and nuclear fraction (B). Proteins that were found to be increased or decreased in abundance in the cytoplasmic or nuclear fraction were submitted to network analysis using Ingenuity Systems. Green color indicated proteins showing 0.83 or greater decrease in abundance, and red color showing 1.2 or greater increase in IBDV‐infected cells. Different shapes represented different functional class of the proteins. Solid lines and dashed lines indicated, respectively, direct or indirect molecular interaction.